You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

CLINICAL TRIALS PROFILE FOR ICP-022

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for ICP-022

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT03189017 ↗	A Phase I Study of ICP-022 in Healthy Subjects	Completed	Innocare Pharma Australia Pty Ltd	Phase 1	This is a single center, randomized, double-blind, placebo-controlled, dose escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ICP-022 following oral single and multiple escalating dose administration.
NCT03493217 ↗	A Study to Evaluate ICP-022 in Patients With CLL/ SLL	Active, not recruiting	Beijing InnoCare Pharma Tech Co., Ltd.	Phase 1/Phase 2	The phase I/II clinical study is to investigate the safety, tolerability and efficacy of ICP-022 in R/R CLL/SLL patients.
NCT03494179 ↗	A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)	Active, not recruiting	Beijing InnoCare Pharma Tech Co., Ltd.	Phase 1/Phase 2	The phase I/II clinical study is to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of ICP-022.
NCT03797456 ↗	A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)	Recruiting	Beijing InnoCare Pharma Tech Co., Ltd.	Phase 2	The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R MZL will be evaluated in approximately 80 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.
NCT04014205 ↗	A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies	Recruiting	Beijing InnoCare Pharma Tech Co., Ltd.	Phase 1/Phase 2	This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell malignancies. The study contains two parts, Part 1 (dose escalation) and Part 2 (dose expansion).
NCT04304040 ↗	A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma	Recruiting	Beijing InnoCare Pharma Tech Co., Ltd.	Phase 1/Phase 2	Dose escalation and expansion phase I/IIa clinical study of recombinant humanized type II CD20 monoclonal antibody MIL62 injection combined with a novel selective Bruton Tyrosine Kinase(BTK) inhibitor Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for ICP-022

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Systemic Lupus Erythematosus	2
Mantle Cell Lymphoma	2
Chronic Lymphocytic Leukemia	2
Small Lymphocytic Lymphoma	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Lymphoma	9
Lymphoma, B-Cell	3
Leukemia, Lymphoid	3
Leukemia, Lymphocytic, Chronic, B-Cell	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for ICP-022

Trials by Country

Map
Table

Trials by Country
Location	Trials
China	97
United States	14
Australia	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
Tennessee	1
Ohio	1
New York	1
New Jersey	1
Nebraska	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for ICP-022

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	7
Phase 1/Phase 2	5
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	8
Not yet recruiting	4
Active, not recruiting	2
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ICP-022

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Beijing InnoCare Pharma Tech Co., Ltd.	12
Innocare Pharma Australia Pty Ltd	1
Shandong University	1
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	13
Other	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.